Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | ACACB | O00763 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | CSK | P41240 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14884551 | 1.00 | HDAC1 (0.51) | HDAC1HDAC6ALDH1A1ACACBESR1 | |
| SCHEMBL3995126 | 1.00 | HDAC1 (0.51) | HDAC1HDAC6ALDH1A1ACACBESR1 | |
| Hydrochloric Acid SCHEMBL3998750 | 0.98 | ALDH1A1 (0.52) | HDAC1HDAC6ALDH1A1ACACBESR1 | |
| Hydrochloric Acid SCHEMBL3972036 | 0.98 | ALDH1A1 (0.52) | HDAC1HDAC6ALDH1A1ACACBESR1 | |
| Hydrochloric Acid SCHEMBL16061012 | 0.98 | ALDH1A1 (0.52) | HDAC1HDAC6ALDH1A1ACACBESR1 | |
| SCHEMBL3742216 | 0.85 | ACACB (0.42) | HDAC1HDAC6ACACBCSKSLC7A5 | |
| SCHEMBL839117 | 0.85 | MMP8 (0.44) | HDAC1HDAC6ACACBSLC7A5MEN1 | |
| SCHEMBL839784 | 0.85 | MMP8 (0.44) | HDAC1HDAC6ACACBSLC7A5MEN1 | |
| SCHEMBL4881644 | 0.85 | MMP8 (0.44) | HDAC1HDAC6ACACBSLC7A5MEN1 | |
| SCHEMBL24648908 | 0.84 | ALDH1A1 (0.51) | ALDH1A1ACACBESR1ESR2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106188224-A | A kind of multiple target-point anti-cancer medicine and preparation method and application | 广东工业大学 | 2016-12-07 | — | — | CN | claimed |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY ST LOUIS (US) | 2025-12-18 | — | — | US | disclosed |
| WO-2023250339-A2 | VLA4 INHIBITORS AND USES THEREOF | WASHINGTON UNIVERSITY (US) | 2023-12-28 | — | — | WO | disclosed |
| CN-113825748-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2021-12-21 | — | — | CN | disclosed |
| CN-105142635-B | Heterocyclic compounds useful for the treatment of diseases | 艾匹根生物技术有限公司 | 2021-07-27 | — | — | CN | disclosed |
| EP-3426648-B1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2021-05-12 | — | — | EP | disclosed |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | CTXT PTY LTD (AU) | 2019-09-24 | — | — | US | disclosed |
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LTD (AU) | 2019-03-07 | — | — | US | disclosed |
| EP-3426648-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | Ctxt Pty Ltd (AU) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153513-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | CTXT PTY LIMITED (AU) | 2017-09-14 | — | — | WO | disclosed |
| US-7122580-B2 | Aryl and heteroaryl compounds and methods to modulate coagulation | TRANSTECH PHARMA, INC. (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1660439-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Transtech Pharma, Inc. (US) | 2006-05-31 | — | — | EP | disclosed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
| WO-2005014533-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014534-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | disclosed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| CN-1288457-A | Inhibitors of & alpha, 4 mediated cell adhesion | TANABE SEIYAKU CO (JP) | 2001-03-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | HDAC1 1637/4885HDAC6 456/4885ALDH1A1 3511/4885 |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | HDAC1 831/4885HDAC6 1067/4885ALDH1A1 2886/4885 |
| US-20190071425-A1 | TETRAHYDROISOQUINOLINES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | HDAC1 98/4885HDAC6 1241/4885ALDH1A1 4294/4885 |
| US-10421743-B2 | Tetrahydroisoquinolines as PRMT5 inhibitors | PRMT5, PRMT1, PRMT3 | HDAC1 98/4885HDAC6 1241/4885ALDH1A1 4294/4885 |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | HDAC1 1171/4885HDAC6 1063/4885ALDH1A1 711/4885 |
| US-20250381168-A1 | VLA4 INHIBITORS AND USES THEREOF | CXCR4, SDF4, ITGB4 | HDAC1 2445/4885HDAC6 1044/4885ALDH1A1 523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.